Next-generation weight-loss pills could hit the market in the coming months, with new data raising a key question: Will patients embrace a more convenient alternative to injecting themselves, even if it means losing less weight?

A former college athlete, 51-year-old Charles never thought he'd have to worry about his weight. But football injuries and a sedentary adulthood drove up his weight — until he started taking Zepbound.

Eli Lilly says their obesity pill led to more than 12% weight loss in closely watched late-stage trial, paving way for approval. Patients taking the pill called orforglipron, an oral GLP-1 receptor, lost almost 12% of their body weight,